Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
Open Access
- 27 July 2018
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 105 (2) , 496-504
Abstract
In randomized clinical trials (RCTs) proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors showed a favorable safety profile, however, “real‐world” data on adverse events (AEs) is scarce. Three datasets, a hospital registry (n = 164), and two Pharmacovigilance databases, Lareb (n = 149) and VigiLyze (n = 15,554), reporting AEs attributed to PCSK9 inhibitors (alirocumab or evolocumab) prescribed in clinical practice were analyzed. In the hospital registry, 41.5% of the patients reported any AE, most often injection‐site reactions (33.8%) and influenza‐like illness (27.9%). Twelve patients (7%) discontinued PCSK9 inhibitor treatment. Most common AE reported in the Lareb and VigiLyze database was myalgia (12.8% and 8.3%, respectively). No clinically relevant differences in gender or between drugs were observed. No specific subgroup of patients could be identified at risk of developing AEs. During follow‐up, AEs resolved in most patients (71.1%). In a real‐world setting, PCSK9 inhibitors are well tolerated with an overall safety profile comparable to RCTs.Keywords
This publication has 35 references indexed in Scilit:
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsBMC Medicine, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathwayAtherosclerosis, 2013
- Unerwünschte Arzneimittelreaktionen auf BiologikaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- Adverse drug reactions to biologicsJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- Beyond the Randomized Clinical TrialCirculation, 2008
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in FranceFundamental & Clinical Pharmacology, 2002
- Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studiesBritish Journal of Clinical Pharmacology, 1998